Novo Nordisk advances obesity candidate to late stage program after weight loss of less than 12% Subcutaneous Cagrilintide, Semaglutide Shows Significant Weight Loss in Type 2 Diabetes Trial Pharmacy Times No change' for CagriSema as Novo ditches single chamber device Cagrilintide is an amylin analogue that helps regulate appetite. In a randomized trial of over 3400 patients who were overweight or obese and had 1 weight related complication, individuals assigned to a combination Good looking results for Novo Nordisk's combo of GLP1ra semaglutide (known as #ozempic for #diabetes & #wegovy for obesity) + Cagrilintide (amylin agonist) to achieve #weightloss in obesity and obesity with type Novo Nordisk launches trial of pipeline drug CagriSema versus newly approved Zepbound Clinical Trials Arena